Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Arthritis Rheum. 2010 Aug;62(8):2525–2529. doi: 10.1002/art.27516

Table 1.

Founders with excessive risk of descendants with JIA

Founder FSIR P value Descendants JIA subtypes Onset age Mean (range) Female N (%) ANA + N
Total with JIA expected S R P O E Ps U
1 4.03 0.004 6266 6 1.5 3 3 4.4 (0.9–8.6) 6 (100) 3
2 4.03 0.004 5272 5 1.5 2 2 1 4.3 (0.9–8.6) 4 (80) 3
3 2.48 0.002 21517 13 5.6 1 2 2 5 3 8.1 (1.7–15.7) 8 (62) 4
4 3.50 0.005 5878 6 2.0 1 2 2 1 9.5 (1.1–15.7) 5 (83) 1
5 4.32 0.007 3915 5 1.2 2 2 1 9.5 (1.7–15.7) 4 (80) 1
6 2.49 0.008 17389 10 4.0 3 4 2 1 9.2 (1.1–15.3) 5 (50) 1
7 2.88 0.008 10875 8 2.8 1 1 1 5 6.8 (2.2–12.5) 3 (50) 3
8 5.42 0.001 4646 6 1.1 1 2 2 1 9.9 (2.7–15.6) 5 (83) 3
9 7.04 0.0003 3455 6 0.9 1 2 2 1 9.9 (2.7–15.6) 5 (83) 3
10 6.85 0.0001 5185 7 1.0 1 2 3 1 8.1 (1.3–15.8) 6 (86) 3
11 4.23 0.002 7536 7 1.7 1 2 3 1 8.1 (1.3–15.8) 6 (86) 3
12 4.43 0.006 5726 5 1.1 1 1 3 4.8 (1.3–13.1) 4 (80) 2
13 9.51 0.0002 2058 5 0.5 1 3 1 6.3 (1.4–13.6) 5 (100) 3
14 5.40 0.003 2868 5 0.9 2 2 1 7.2 (0.3–13.3) 3 (60) 4
15 4.30 0.007 4944 5 1.2 1 1 1 2 6.1 (1.3–13.3) 4 (80) 2
16 3.36 0.002 12763 9 2.7 1 1 2 4 1 7.6 (0.8–15.4) 7 (78) 5
17 3.63 0.007 7251 5 1.7 4 1 6.1 (2.6–9.0) 3 (60) 1
18 4.29 0.003 6120 5 1.4 4 1 6.1 (2.6–9.0) 3 (60) 1
19 3.73 0.003 7151 7 1.9 1 3 3 7.8 (2.2–14.0) 3 (43) 2
20 7.00 0.0009 2266 5 0.7 1 1 2 1 7.7 (3.7–10.0) 4 (80) 1
21 3.97 0.005 5491 6 1.5 1 2 1 1 1 8.1 (3.6–13.2) 5 (83) 2
22 5.31 0.003 3735 5 0.9 1 1 1 1 1 6.7 (1.3–13.6) 2 (40) 2

Founders are defined as individuals for whom there are no ancestral genealogical relationships in the Utah Population Database. Thus, they are the earliest generation in the database. FSIR: familial standardized incidence ratio. JIA subtypes: S = systemic JIA, R = RF + polyarticular JIA; P = RF negative polyarticular JIA, O = oligoarticular JIA, E = enthesitis related arthritis, Ps = psoriatic JIA, U = undifferentiated JIA. ANA: Anti nuclear antibody.